- All Courts
- Federal Courts
- Bankruptcies
- PTAB
- ITC
Filters
Like full text docket searches?
Get docket alerts, perform legal research, get updates of major decisions and orders, use our advanced analytics, and more. Request a Demo or create your account.
Date Filed
Dollars
Find cases based on dollar amount with searches like:
$100k-$10M.
Read the details here.
Displaying 804-818 of
973 results
1110 Exhibit: Exhibit 1110 Karagiannis
Document
IPR2023-00724, No. 1110 Exhibit - Exhibit 1110 Karagiannis (P.T.A.B. May. 22, 2024)
|
|
Cite Document
1143 Exhibit: Exhibit 1143 James
Document
IPR2023-00724, No. 1143 Exhibit - Exhibit 1143 James (P.T.A.B. May. 22, 2024)
|
|
Cite Document
2091 Exhibit: EX2091 Das, SR, et al, ACC Expert Consensus Decision Pathway on ...
Document
IPR2023-00724, No. 2091 Exhibit - EX2091 Das, SR, et al, ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients with Type 2 Diabetes and...
|
|
Cite Document
2467 Exhibit: EX2467 US Food Drug Administration, DrugsFDA, Steglujan
Document
IPR2023-00724, No. 2467 Exhibit - EX2467 US Food Drug Administration, DrugsFDA, Steglujan (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2100 Exhibit: EX2100 Leiter, LA, et al, Cardiovascular risk reduction with once wee...
Document
IPR2023-00724, No. 2100 Exhibit - EX2100 Leiter, LA, et al, Cardiovascular risk reduction with once weekly semaglutide in subjects with type 2 diabetes a post hoc analysis of gender, age, and ...
|
|
Cite Document
2507 Exhibit: EX2507 Novo Nordisk, Financial report for the period 1 January 2021...
Document
IPR2023-00724, No. 2507 Exhibit - EX2507 Novo Nordisk, Financial report for the period 1 January 2021 to 30 June 2021 Aug 4, 2021 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2438 Exhibit: EX2438 Hoerman, J, “Tanzeum albiglutide Discontinued After FDA W...
Document
IPR2023-00724, No. 2438 Exhibit - EX2438 Hoerman, J, “Tanzeum albiglutide Discontinued After FDA Warns of Risk of Anaphylaxis Reaction,” httpstrulawcomfdatanzeum albiglutide anaphylaxi...
|
|
Cite Document
2398 Exhibit: EX2398 Januvia® Prescribing Information rev Feb 2018
Document
IPR2023-00724, No. 2398 Exhibit - EX2398 Januvia® Prescribing Information rev Feb 2018 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2477 Exhibit: EX2477 US Food Drug Administration, DrugsFDA, Brenzavvy
Document
IPR2023-00724, No. 2477 Exhibit - EX2477 US Food Drug Administration, DrugsFDA, Brenzavvy (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2364 Exhibit: EX2364 US Food Drug Administration, DrugsFDA, Glucotrol®
Document
IPR2023-00724, No. 2364 Exhibit - EX2364 US Food Drug Administration, DrugsFDA, Glucotrol® (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2095 Exhibit: EX2095 Evans, LM, et al, A population adjusted indirect comparison ...
Document
IPR2023-00724, No. 2095 Exhibit - EX2095 Evans, LM, et al, A population adjusted indirect comparison of cardiovascular benefits of once weekly subcutaneous semaglutide and dulaglutide in ...
|
|
Cite Document
2528 Exhibit: EX2528 Eli Lilly Co, SEC Form 10 Q for the Quarter Ended March 31,...
Document
IPR2023-00724, No. 2528 Exhibit - EX2528 Eli Lilly Co, SEC Form 10 Q for the Quarter Ended March 31, 2023 Apr 27, 2023 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2401 Exhibit: EX2401 US Food Drug Administration, DrugsFDA, Janumet®
Document
IPR2023-00724, No. 2401 Exhibit - EX2401 US Food Drug Administration, DrugsFDA, Janumet® (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2054 Exhibit: EX2054 Declaration of Robin S Goland, MD
Document
IPR2023-00724, No. 2054 Exhibit - EX2054 Declaration of Robin S Goland, MD (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
3003 Exhibit: Email from Megan Raymond To Trials Cc white ptabBeel, Bryan D gre...
Document
IPR2023-00724, No. 3003 Exhibit - Email from Megan Raymond To Trials Cc white ptabBeel, Bryan D greb ptab prochnowptab jones ptab tietz pta lembo ptab Novo Semaglutide Subject IPR2023...
|
|
Cite Document
